

Technology Appraisal Committee D Interests Register

Pembrolizumab for previously treated advanced or metastatic urothelial cancer - CDF review TA519 [ID1536]

Publication Date: 28/04/2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Mrs Amanda Matse-Orere	TAC Committee Member	Financial	Works for Roche Diagnostics, part of an umbrella of companies that includes Roche Products, that manufactures a competitor to pembrolizumab.	N/A	22/10/2019	N/A	Mrs Matse-Orere was absent from the discussion as a non-financial professional and personal interest prevented her from participating in this section of the meeting.